Table 1.
Clinicopathologic characteristics of patients enrolled in the study.
| Overall (n = 28) | ||
|---|---|---|
| N | % | |
| Gender | ||
| Female | 26 | 92.9% |
| Male | 2 | 7.1% |
| Age | ||
| Mean (SD) | 61.5 (9.2) | |
| Median (IQR) [min, max] | 65 (11.3) [45,78] | |
| Race | ||
| White | 25 | 89.3% |
| Asian | 1 | 3.6% |
| Unknown | 2 | 7.1% |
| Ethnicity | ||
| Not Hispanic or Latino | 28 | 100% |
| ECOG performance status | ||
| 0 = asymptomatic and fully active | 17 | 60.7% |
| 1 = symptomatic; fully ambulatory; restricted in physically strenuous activity | 11 | 39.3% |
| Primary site of disease | ||
| Ovary | 18 | 64.3% |
| Uterus | 5 | 17.9% |
| Colon | 2 | 7.1% |
| Breast | 1 | 3.6% |
| Melanoma | 1 | 3.6% |
| Malignant solitary fibrous tumour | 1 | 3.6% |
| Stage at diagnosis | ||
| IC | 1 | 3.6% |
| IIC | 1 | 3.6% |
| III | 3 | 10.7% |
| IIIC | 5 | 17.9% |
| IV | 14 | 50% |
| IVB | 4 | 14.3% |
| Histology | ||
| Well differentiated | 2 | 7.1% |
| Moderately differentiated | 2 | 7.1% |
| Poorly differentiated | 15 | 53.6% |
| Grade cannot be assessed/unknown | 9 | 32.1% |
| Lines of prior therapy | ||
| Median [min, max] | 5.5 | 1–15 |